Trend Psychedelic developers converge on FDA approval as the main route to scale

Summary

GWI's Psychedelics and Healing Initiative reports that the field has largely moved away from its counter-culture roots toward the regulated medical route. Most practitioners now see medicines approved and regulated by the FDA as the most effective way to reach people in greatest need. Daniel Goldberg of Palo Santo argues that serving more than a billion people will require real integration into the health system, including insurance reimbursement, despite that system's flaws. He also says the FDA has proved genuinely receptive to new psychedelic compounds. The Initiative backs this with a count of eight candidates holding breakthrough therapy designation and seven in Phase 3 trials. It frames regulatory integration, not informal delivery, as the field's main strategy for 2026.